| Advanced and Metastatic Breast Cancer |
1 |
0.92 |
| Breast Cancer |
0 |
1 |
| Biologic Therapy |
0 |
0.82 |
| Genomic Medicine |
0 |
0.8 |
| Hepatocellular Carcinoma |
0 |
0.78 |
| Lung Cancer |
0 |
0.76 |
| Bone Metastasis |
0 |
0.73 |
| Ovarian Cancer |
0 |
0.71 |
| Prostate Cancer |
0 |
0.66 |
| Colorectal Cancer |
0 |
0.61 |
| Cancer |
0 |
0.6 |
| Tumor |
0 |
0.56 |
| Triple Negative Breast Cancer |
0 |
0.55 |
| Metastasis |
0 |
0.53 |
| Targeted Cancer Therapy |
0 |
0.47 |
| Liver Metastases |
0 |
0.46 |
| Cancer Risk |
0 |
0.44 |
| Colon Cancer |
0 |
0.44 |
| Tumor Genetics |
0 |
0.38 |
| Breast |
0 |
0.33 |
| Biomarker |
0 |
0.31 |
| Receptors |
0 |
0.21 |
| Epidermal Growth Factor Receptor |
0 |
0.16 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.14 |
| Estrogen |
0 |
0.14 |
| HIV Infection |
0 |
0.14 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.1 |
| Aromatase Inhibitors |
0 |
0.09 |
| mTOR Inhibitor |
0 |
0.09 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.08 |
| Tyrosine Kinase Inhibitor |
0 |
0.08 |
| Genetic Testing |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.06 |
| Genetics |
0 |
0.06 |
| Biopsy |
0 |
0.04 |
| Bone |
0 |
0.04 |
| Insurance |
0 |
0.04 |
| KRAS |
0 |
0.04 |
| Liver |
0 |
0.04 |
| Prostate |
0 |
0.04 |
| Testosterone |
0 |
0.04 |
| Medical Life |
0 |
0.03 |
| Social Determinants of Health |
0 |
0.03 |
| California |
0 |
0.02 |
| Chemotherapy |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| DNA Sequencing |
0 |
0.02 |
| Endocrine Therapy |
0 |
0.02 |
| Fluorescent In Situ Hybridization |
0 |
0.02 |
| Food and Drug Administration (FDA) |
0 |
0.02 |
| Hand |
0 |
0.02 |
| Health Care Quality, Access, and Evaluation |
0 |
0.02 |
| Immunohistochemistry |
0 |
0.02 |
| Lung |
0 |
0.02 |
| Match |
0 |
0.02 |
| Polymerase Chain Reaction |
0 |
0.02 |
| Prognosis |
0 |
0.02 |
| Somatic |
0 |
0.02 |
| Tissue |
0 |
0.02 |
| Tyrosine Kinase |
0 |
0.02 |